VolitionRx webinar: Unravelling the web of NETs in sepsis

Join intensive care specialist and haematology key opinion leader Dr Andrew Retter as he helps us understand:

• the burden of sepsis and challenges in treatment and patient care;
• the connection between NETosis and sepsis;
• the future of tools and treatments, as well as the potential role of NETs in other disease areas; and
• the role of Volition’s diagnostics tools to address unmet need in the space.

Chairing the panel and Q&A will be Soo Romanoff, Managing Director of Healthcare at Edison Group.

Event details

Date: 2 May 2023

Time: 11am EST/4pm BST/5pm CET

If you would like more information, please refer to our research reports.

For more information on VolitionRX, browse the company’s website before the event.

About VolitionRX
VolitionRX is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, in both humans and other animals, including some cancers and diseases associated with NETosis such as sepsis and COVID-19.

Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

Volition’s research and development activities are centred in Belgium, with an innovation laboratory and office in the US and additional offices in London and Singapore.